Eloxx Pharmaceuticals Inc (ELOX)

$11.01 +4.81 (77.58%)
Market Cap 1.88M
Revenue (ttm) 0.00
Net Income (ttm) -6.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 283,900
Avg Vol 8,122
Day's Range N/A - N/A
Shares Out 5.07M
Stochastic %K 94%
Beta -1,907.33
Analysts Strong Buy
Price Target $30.00

Company Profile

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, an...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 577 5300
Address:
P.O. Box 274, Arlington, United States
MingChoo
MingChoo Sep. 13 at 2:11 PM
$ELOX Upside potential8
0 · Reply
BioTuesdays
BioTuesdays Sep. 11 at 9:47 PM
$ELOX has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS). https://biotuesdays.com/2026/09/11/eloxx-announces-first-patients-dosed-in-study-of-exaluren-in-nmas/
0 · Reply
STACKD0E
STACKD0E Sep. 11 at 12:19 PM
$ELOX 👁
0 · Reply
focafoca99
focafoca99 Sep. 11 at 11:51 AM
$ELOX started its Phase 2b EXACT study with the first two patients dosed in the Alport syndrome trial.
0 · Reply
Theybleedred
Theybleedred Aug. 11 at 2:46 PM
$ELOX here we go !!
0 · Reply
CamilaCruze
CamilaCruze Aug. 7 at 11:02 PM
$ELOX The Phase 2b Alport data is the key one. If exaluren produces convincing clinical results… ELOX could potentially be revalued dramatically because it's currently a clinical-stage company.
0 · Reply
Napoleon1335
Napoleon1335 Aug. 4 at 1:10 PM
$ELOX to the moon!
0 · Reply
Myusername123_
Myusername123_ Aug. 2 at 10:50 AM
$ELOX anyone with insight on this one?
0 · Reply
Bigeyes2
Bigeyes2 Jul. 31 at 7:57 PM
$ELOX cup no handle
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 31 at 6:28 PM
$MVIS $ZEO $ELOX $INBS $SCYX 👀
0 · Reply
Latest News on ELOX
Eloxx Pharmaceuticals files to sell 600,000 shares of common stock for holders

2026-09-11T21:35:21.000Z - 2 days ago

Eloxx Pharmaceuticals files to sell 600,000 shares of common stock for holders

Eloxx Pharmaceuticals Registration statement: Registration filing

Sep 11, 2026, 8:00 AM EDT - 2 days ago

Eloxx Pharmaceuticals Registration statement: Registration filing

Eloxx Pharmaceuticals says first patients dosed in Phase 2b Exact Study

2026-09-11T11:35:37.000Z - 2 days ago

Eloxx Pharmaceuticals says first patients dosed in Phase 2b Exact Study

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Sep 11, 2026, 7:30 AM EDT - 2 days ago

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital

2026-08-20T10:20:26.000Z - 24 days ago

Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 12, 2026, 6:00 AM EDT - 4 weeks ago

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

Eloxx Pharmaceuticals Quarterly report: Q2 2026

Eloxx Pharmaceuticals Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

Eloxx Pharmaceuticals Earnings release: Q2 2026

Eloxx Pharmaceuticals initiated with an Outperform at LifeSci Capital

2026-07-22T11:50:13.000Z - 7 weeks ago

Eloxx Pharmaceuticals initiated with an Outperform at LifeSci Capital

Eloxx Pharmaceuticals initiated with a Buy at Guggenheim

2026-07-20T09:15:15.000Z - 7 weeks ago

Eloxx Pharmaceuticals initiated with a Buy at Guggenheim

Eloxx Pharmaceuticals initiated with a Buy at Guggenheim

2026-07-20T00:45:05.000Z - 1 month ago

Eloxx Pharmaceuticals initiated with a Buy at Guggenheim

Eloxx Pharmaceuticals Inc trading resumes

2026-07-09T15:25:10.000Z - 2 months ago

Eloxx Pharmaceuticals Inc trading resumes

Eloxx Pharmaceuticals Inc trading halted, volatility trading pause

2026-07-09T15:20:17.000Z - 2 months ago

Eloxx Pharmaceuticals Inc trading halted, volatility trading pause

Eloxx Pharmaceuticals Inc trading resumes

2026-06-16T18:25:09.000Z - 2 months ago

Eloxx Pharmaceuticals Inc trading resumes

Eloxx Pharmaceuticals Inc trading halted, volatility trading pause

2026-06-16T18:20:30.000Z - 2 months ago

Eloxx Pharmaceuticals Inc trading halted, volatility trading pause

Eloxx Pharmaceuticals Inc trading halted, volatility trading pause

2026-06-11T09:06:37.000Z - 3 months ago

Eloxx Pharmaceuticals Inc trading halted, volatility trading pause

Eloxx Pharmaceuticals Inc trading resumes

2026-06-11T09:06:11.000Z - 3 months ago

Eloxx Pharmaceuticals Inc trading resumes

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Jun 8, 2026, 9:23 PM EDT - 3 months ago

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Eloxx Pharmaceuticals Registration statement: Registration filing

Jun 4, 2026, 8:00 AM EDT - 3 months ago

Eloxx Pharmaceuticals Registration statement: Registration filing

Eloxx Pharmaceuticals Registration statement: Registration filing

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Eloxx Pharmaceuticals Registration statement: Registration filing

Eloxx Pharmaceuticals Registration statement: Registration filing

May 7, 2026, 8:00 AM EDT - 4 months ago

Eloxx Pharmaceuticals Registration statement: Registration filing

Eloxx Pharmaceuticals Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

Eloxx Pharmaceuticals Quarterly report: Q1 2026

Eloxx Pharmaceuticals Annual report: Q4 2025

Mar 17, 2026, 8:00 AM EDT - 6 months ago

Eloxx Pharmaceuticals Annual report: Q4 2025

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Jul 11, 2024, 11:46 AM EDT - 2 years ago

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates

2024-04-16T11:33:21.000Z - 2 years ago

Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Apr 16, 2024, 7:30 AM EDT - 2 years ago

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Eloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status

2024-04-10T15:56:40.000Z - 2 years ago

Eloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Mar 13, 2024, 11:42 AM EDT - 2 years ago

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

Mar 13, 2024, 11:33 AM EDT - 2 years ago

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

Eloxx Pharmaceuticals Registration statement: Registration filing

Jan 25, 2024, 7:00 AM EST - 2 years ago

Eloxx Pharmaceuticals Registration statement: Registration filing

Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders

2024-01-25T11:12:07.000Z - 2 years ago

Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Eloxx Pharmaceuticals Quarterly report: Q3 2023

Eloxx Pharmaceuticals Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Eloxx Pharmaceuticals Earnings release: Q3 2023

Eloxx Pharmaceuticals price target lowered to $30 from $60 at Oppenheimer

2023-11-02T12:40:54.000Z - 2 years ago

Eloxx Pharmaceuticals price target lowered to $30 from $60 at Oppenheimer

Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA

2023-10-09T12:18:11.000Z - 2 years ago

Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Oct 9, 2023, 8:00 AM EDT - 2 years ago

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals provides updates on ELX-02, ZKN-013

2023-09-07T13:04:31.000Z - 3 years ago

Eloxx Pharmaceuticals provides updates on ELX-02, ZKN-013

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Sep 7, 2023, 9:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Aug 14, 2023, 8:30 AM EDT - 3 years ago

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals Quarterly report: Q2 2023

Aug 11, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Quarterly report: Q2 2023

Eloxx Pharmaceuticals Earnings release: Q2 2023

Aug 11, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Earnings release: Q2 2023

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Aug 3, 2023, 9:26 AM EDT - 3 years ago

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Jul 10, 2023, 9:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

Jun 28, 2023, 9:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

Eloxx Pharmaceuticals Transcript: Study result

Jun 27, 2023, 11:30 AM EDT - 3 years ago

Eloxx Pharmaceuticals Transcript: Study result

Eloxx Pharmaceuticals Slides: Study result

Jun 27, 2023, 11:30 AM EDT - 3 years ago

Eloxx Pharmaceuticals Slides: Study result

Eloxx Pharmaceuticals Press release: Study result

Jun 27, 2023, 11:30 AM EDT - 3 years ago

Eloxx Pharmaceuticals Press release: Study result

Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome

Jun 21, 2023, 1:30 PM EDT - 3 years ago

Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome

Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Jun 21, 2023, 9:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Jun 14, 2023, 4:53 PM EDT - 3 years ago

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study

May 24, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study

Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

May 15, 2023, 4:30 PM EDT - 3 years ago

Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q1 2023

May 12, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Quarterly report: Q1 2023

Eloxx Pharmaceuticals Earnings release: Q1 2023

May 12, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Earnings release: Q1 2023

Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013

May 2, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update

Apr 3, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Annual report: Q4 2022

Mar 31, 2023, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Annual report: Q4 2022

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

Mar 28, 2023, 4:45 PM EDT - 3 years ago

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 6, 2023, 4:10 PM EST - 3 years ago

Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed

Feb 27, 2023, 4:05 PM EST - 3 years ago

Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

Jan 25, 2023, 8:00 AM EST - 3 years ago

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

Dec 1, 2022, 8:45 AM EST - 3 years ago

Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update

Nov 10, 2022, 5:15 PM EST - 3 years ago

Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q3 2022

Nov 10, 2022, 7:00 AM EST - 3 years ago

Eloxx Pharmaceuticals Quarterly report: Q3 2022

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Nov 1, 2022, 4:30 PM EDT - 3 years ago

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Oct 17, 2022, 8:00 AM EDT - 3 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Sep 14, 2022, 4:05 PM EDT - 4 years ago

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update

Aug 15, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q2 2022

Aug 12, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Quarterly report: Q2 2022

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Jul 5, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

May 10, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q1 2022

May 6, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Quarterly report: Q1 2022

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Mar 31, 2022, 7:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Mar 30, 2022, 4:15 PM EDT - 4 years ago

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Annual report: Q4 2021

Mar 30, 2022, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Annual report: Q4 2021

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

Mar 29, 2022, 7:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

Nov 17, 2021, 7:00 AM EST - 4 years ago

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

Nov 9, 2021, 8:00 AM EST - 4 years ago

Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q3 2021

Nov 8, 2021, 7:00 AM EST - 4 years ago

Eloxx Pharmaceuticals Quarterly report: Q3 2021

Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

Oct 7, 2021, 4:15 PM EDT - 4 years ago

Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

Oct 5, 2021, 8:00 AM EDT - 4 years ago

Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

Eloxx Pharmaceuticals Registration statement: Registration filing

Aug 20, 2021, 8:00 AM EDT - 5 years ago

Eloxx Pharmaceuticals Registration statement: Registration filing

Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Aug 16, 2021, 4:05 PM EDT - 5 years ago

Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Quarterly report: Q2 2021

Aug 16, 2021, 8:00 AM EDT - 5 years ago

Eloxx Pharmaceuticals Quarterly report: Q2 2021

Hemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board Observer

Jul 26, 2021, 2:00 AM EDT - 5 years ago

Hemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board Observer

Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Jul 6, 2021, 4:15 PM EDT - 5 years ago

Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

May 18, 2021, 2:15 PM EDT - 5 years ago

Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

May 14, 2021, 7:00 AM EDT - 5 years ago

Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

Eloxx Pharmaceuticals Quarterly report: Q1 2021

May 7, 2021, 8:00 AM EDT - 5 years ago

Eloxx Pharmaceuticals Quarterly report: Q1 2021

Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

May 6, 2021, 5:15 PM EDT - 5 years ago

Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Apr 29, 2021, 4:15 PM EDT - 5 years ago

Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Apr 1, 2021, 8:00 AM EDT - 5 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Apr 1, 2021, 8:00 AM EDT - 5 years ago

Eloxx Pharmaceuticals Proxy statement: Proxy filing

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

Apr 1, 2021, 7:45 AM EDT - 5 years ago

Eloxx Pharmaceuticals Acquires Zikani Therapeutics

MingChoo
MingChoo Sep. 13 at 2:11 PM
$ELOX Upside potential8
0 · Reply
BioTuesdays
BioTuesdays Sep. 11 at 9:47 PM
$ELOX has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS). https://biotuesdays.com/2026/09/11/eloxx-announces-first-patients-dosed-in-study-of-exaluren-in-nmas/
0 · Reply
STACKD0E
STACKD0E Sep. 11 at 12:19 PM
$ELOX 👁
0 · Reply
focafoca99
focafoca99 Sep. 11 at 11:51 AM
$ELOX started its Phase 2b EXACT study with the first two patients dosed in the Alport syndrome trial.
0 · Reply
Theybleedred
Theybleedred Aug. 11 at 2:46 PM
$ELOX here we go !!
0 · Reply
CamilaCruze
CamilaCruze Aug. 7 at 11:02 PM
$ELOX The Phase 2b Alport data is the key one. If exaluren produces convincing clinical results… ELOX could potentially be revalued dramatically because it's currently a clinical-stage company.
0 · Reply
Napoleon1335
Napoleon1335 Aug. 4 at 1:10 PM
$ELOX to the moon!
0 · Reply
Myusername123_
Myusername123_ Aug. 2 at 10:50 AM
$ELOX anyone with insight on this one?
0 · Reply
Bigeyes2
Bigeyes2 Jul. 31 at 7:57 PM
$ELOX cup no handle
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 31 at 6:28 PM
$MVIS $ZEO $ELOX $INBS $SCYX 👀
0 · Reply
titanmaximum2
titanmaximum2 Jul. 9 at 4:28 PM
$ELOX Flash crash and halt on no news.
0 · Reply
Spacedoutt
Spacedoutt Jul. 1 at 3:47 PM
$SDOT bring some to $ELOX
0 · Reply
Spacedoutt
Spacedoutt Jul. 1 at 3:07 PM
$KUST anyone know if the mc on $ELOX is correct ?
0 · Reply
Spacedoutt
Spacedoutt Jul. 1 at 1:34 PM
$ELOX wtf is this what is the real market cap holy 😳
0 · Reply
topstockalerts
topstockalerts Jun. 13 at 12:41 AM
$ELOX the trend is building without much fanfare.
0 · Reply
appichaurasia
appichaurasia Jun. 12 at 3:09 PM
$ELOX
0 · Reply
Merlintrader
Merlintrader Jun. 10 at 7:24 AM
$IDYA $IDYA, $STTK, $ELOX: Biotech Funding Window Reopens, But Not All Dilution Looks the Same https://www.merlintrader.com/biotech-funding-window-reopens/
0 · Reply
Peaceouty
Peaceouty Jun. 9 at 9:12 PM
$RDGT Adding to below: Chinese stocks are trending for a reason. China is becoming dominant in the world scene if you like it or not. USA and Europe are heading for a recession while China profits off that misfortune. How to beat inflation? Put money into growth (Asia) and gold. $CCTG $AZI $CHAI $ELOX
2 · Reply
Parobolicbatman
Parobolicbatman Jun. 9 at 8:32 PM
$ELOX what even happened here, can anyone explain lol
0 · Reply